Skip to main content

Table 1 Decrease in antibody level 6 months after drug treatment stratified by age

From: Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration

Age (years)

N

% pgp3 Ab + after 6 mos (CI)

P-value

N

% CT694 Ab + after 6 mos (CI)

P-value

  

IgG

0.06

  

0.28

1

8

22.24 (4.24, 40.25)

0.01

8

36.89 (10.46, 63.32)

0.002

2

5

9.64 (−13.14, 32.41)

0.83

6

32.25 (1.73, 62.77)

0.03

3

14

4.94 (−8.67, 18.54)

0.91

15

18.36 (−0.94, 37.67)

0.07

4

22

9.07 (−1.79, 19.93)

0.15

23

15.59 (0.00, 31.18)

0.05

5

30

12.01 (2.72, 21.31)

0.005

28

16.40 (2.27, 30.53)

0.01

6

26

4.01 (−5.98, 14.00)

0.86

25

0.60 (−14.36, 15.55)

1.00

  

IgA

0.003

  

0.0006

1

7

60.08 (31.36, 88.80)

<0.0001

6

75.06 (40.00, 100.00)

<0.0001

2

5

60.11 (26.12, 94.10)

<0.0001

4

68.85 (25.90, 100.00)

0.0003

3

12

47.91 (25.97, 69.85)

<0.0001

10

34.25 (7.08, 61.41)

0.01

4

14

41.91 (21.60, 62.22)

<0.0001

11

30.93 (5.03, 56.83)

0.01

5

23

45.52 (29.67, 61.37)

<0.0001

20

53.66 (34.45, 72.87)

<0.0001

6

20

52.53 (35.53, 69.52)

<0.0001

17

53.01 (32.17, 73.84)

<0.0001

  1. Values show the mean percentage drop in antibody median fluorescence intensity-background (MFI-BG) for IgG (top section) and IgA (bottom) from baseline to 6 months after drug treatment in paired samples. 95% confident intervals are shown in parentheses. P values testing for a difference from zero (no change) of < 0.05 were considered significant. P values in bold test for an average difference from zero across all age groups.